ADCC-Enhanced Anti-Human C5 (Pozelimab) Antibody (CAT#: BioBet-CB-081LX) Datasheet

C5

Complement C5

This gene encodes a component of the complement system, a part of the innate immune system that plays an important role in inflammation, host homeostasis, and host defense against pathogens. The encoded preproprotein is proteolytically processed to generate multiple protein products, including the C5 alpha chain, C5 beta chain, C5a anaphylatoxin and C5b. The C5 protein is comprised of the C5 alpha and beta chains, which are linked by a disulfide bridge. Cleavage of the alpha chain by a convertase enzyme results in the formation of the C5a anaphylatoxin, which possesses potent spasmogenic and chemotactic activity, and the C5b macromolecular cleavage product, a subunit of the membrane attack complex (MAC). Mutations in this gene cause complement component 5 deficiency, a disease characterized by recurrent bacterial infections. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2015]

C5D; C5a; C5b; ECLZB; CPAMD4

Cell Biology, Immunology,

Protein Based Therapies
Monoclonal antibody (mAb)

IgG4

Pozelimab

Human

Human

ADCC-Enhanced Anti-Human C5 (Pozelimab) Antibody is derived from clone Pozelimab, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the C5, and it is intended for the research of Paroxysmal nocturnal hemoglobinuria .

Paroxysmal nocturnal hemoglobinuria

Similar to the parental antibody Pozelimab, ADCC-Enhanced Anti-Human C5 (Pozelimab) Antibody targets to the antigen C5, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.